Sinovac completed the first patient enrollment in the phase I clinical trial of interferon inhalation solution for children

SHENZHEN, Jan.
11, 2023 /PRNewswire/ -- Recently, Sinovac Pharmaceutical (688136.
SH) successfully completed the first subject enrollment administration, and Sinovac completed another breakthrough
in the field of antiviral medicine.

Interferon (IFN) is a class of proteins with broad-spectrum antiviral, antitumor and immunomodulatory effects, which is a key component of
the body's innate immunity.
Sinovac Pharmaceutical's human interferon α1b inhalation solution is a special drug for children, through atomized administration, the active ingredient can directly reach the lesion, the onset of action is faster, compared with injection, children do not need to bear the pain of injection, acceptance and safety are higher
.
Its indications are pediatric respiratory syncytial virus lower respiratory tract infection (pneumonia, bronchiolitis).

Pediatric respiratory syncytial virus is commonly known as RSV virus, and at present, RSV virus is the cause of respiratory infection, hospitalization and even life-threatening culprit
in children under 5 years of age.
In 2020, 34.
6 million people were severely infected with respiratory syncytial virus in children under 5 years of age worldwide, including 3 million
in China alone.

Human interferon α1b has broad-spectrum antiviral, anti-tumor and immunomodulatory functions, which induces cells to produce a variety of antiviral proteins by binding to cell surface receptors, inhibits the replication of viruses in cells, and enhances the specific cytotoxic effect of macrophages and lymphocytes on target cells by regulating immune function, effectively inhibits the occurrence of virus invasion and infection, enhances the activity of natural killer cells, inhibits the growth of tumor cells, and removes early malignant cells, which plays an indispensable role in antiviral therapy
。

Sinovac Pharmaceutical's human interferon α1b inhalation solution project as a biological agent may fill the market gap of childhood syncytial virus lower respiratory tract infection, and the future market space is huge
.
According to research data from China Insights Consulting, the overall global market size of respiratory syncytial virus drugs is expected to grow from US$1.
9 billion in 2020 to US$11.
7 billion in 2030, with a compound annual growth rate of 19.
9%.

Sinovac Pharmaceutical(688136.
SH) is an innovative international biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein drugs and microecological preparations, the company has been deeply engaged in the field of antiviral for more than 20 years and has achieved great results
。 Its wholly-owned subsidiary Shenzhen Kexing is the first batch of industrialization bases of China's 863 plan achievements, successfully developed the first domestic biological interferon α1b - Serokin and large-scale production, after the product is put into the market, the clinical application field covers respiratory, pediatrics, dermatology, gynecology, hematology and oncology and other departments, its high standard product quality and good efficacy have been widely praised by the market, and the market share has always maintained a leading
position in China 。 According to the statistics of Minai.
com, Sinovac's core product "Seruojin" ranked first
in the domestic market share of short-acting human interferon for injection in 2021 of 30.
33%.

A randomized, double-blind, placebo-controlled safety, tolerability, and pharmacokinetic profile of interferon alfa1b inhalation solution administered in subjects with single dose escalation and continuous multiple dose escalation is currently being carried out
in the cooperation Changsha Third Hospital.